Reversal of aging-induced increases in aortic stiffness by targeting cytoskeletal protein-protein interfaces by Nicholson, Christopher et al.
Boston University
OpenBU http://open.bu.edu
Mechanical Engineering BU Open Access Articles
2018-07-06
Reversal of aging-induced
increases in aortic stiffness by
targeting cytoskele...
This work was made openly accessible by BU Faculty. Please share how this access benefits you.
Your story matters.
Version Published version
Citation (published version): Christopher Nicholson, Kuldeep Singh, Robert Saphirstein, Yuan Gao,
Qian Li, Joanna Chiu, Paul Leavis, Germaine Verwoert, GF Mitchell,
Tyrone Porter, Kathleen Morgan. 2018. "Reversal of aging-induced
increases in aortic stiffness by targeting cytoskeletal protein-protein
interfaces." Journal of the American Heart Association :
Cardiovascular and Cerebrovascular Disease, Volume 7, Issue 15,
https://hdl.handle.net/2144/39043
Boston University
Reversal of Aging-Induced Increases in Aortic Stiffness by Targeting
Cytoskeletal Protein-Protein Interfaces
Christopher J. Nicholson, PhD;* Kuldeep Singh, PhD;* Robert J. Saphirstein, PhD; Yuan Z. Gao, PhD; Qian Li, MS; Joanna G. Chiu, MS;
Paul Leavis, PhD; Germaine C. Verwoert, MSc; G. F. Mitchell, MD; AortaGen Consortium;† Tyrone Porter, PhD; Kathleen G. Morgan, PhD
Background-—The proximal aorta normally functions as a critical shock absorber that protects small downstream vessels from
damage by pressure and flow pulsatility generated by the heart during systole. This shock absorber function is impaired with age
because of aortic stiffening.
Methods and Results-—We examined the contribution of common genetic variation to aortic stiffness in humans by interrogating
results from the AortaGen Consortium genome-wide association study of carotid-femoral pulse wave velocity. Common genetic
variation in the N-WASP (WASL) locus is associated with carotid-femoral pulse wave velocity (rs600420, P=0.0051). Thus, we
tested the hypothesis that decoy proteins designed to disrupt the interaction of cytoskeletal proteins such as N-WASP with its
binding partners in the vascular smooth muscle cytoskeleton could decrease ex vivo stiffness of aortas from a mouse model of
aging. A synthetic decoy peptide construct of N-WASP significantly reduced activated stiffness in ex vivo aortas of aged mice. Two
other cytoskeletal constructs targeted to VASP and talin-vinculin interfaces similarly decreased aging-induced ex vivo active
stiffness by on-target specific actions. Furthermore, packaging these decoy peptides into microbubbles enables the peptides to be
ultrasound-targeted to the wall of the proximal aorta to attenuate ex vivo active stiffness.
Conclusions-—We conclude that decoy peptides targeted to vascular smooth muscle cytoskeletal protein-protein interfaces and
microbubble packaged can decrease aortic stiffness ex vivo. Our results provide proof of concept at the ex vivo level that decoy
peptides targeted to cytoskeletal protein-protein interfaces may lead to substantive dynamic modulation of aortic stiffness. ( J Am
Heart Assoc. 2018;7:e008926. DOI: 10.1161/JAHA.118.008926.)
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V ascular aging is associated with impaired endothelialfunction, low-grade inflammation, and markedly
increased aortic stiffness.1-4 Recent clinical studies document
that increased aortic stiffness, as measured by pulse wave
velocity, is an early and independent biomarker for negative
cardiovascular outcomes such as myocardial infarction,
cognitive decline, and renal disease.2,5-9 Greater aortic
stiffness increases transmission of pressure and flow pul-
satility associated with cardiac contraction into delicate
microvessels, particularly in high-flow organs such as the
brain and kidney.2,3,5,7,9,10 Aortic stiffening (arteriosclerosis)
is distinct from atherosclerosis11 and is thought to cause
secondary morphological changes in microvessels that con-
tribute to the pathogenesis of hypertension and cardiovascu-
lar disease.10,12,13
Aging is associated with fragmentation of elastin and
increased amounts and cross-linking of collagen, all of which
increase the passive stiffness of the extracellular matrix.14,15
However, it has also been proposed that aging of the vascular
smooth muscle cell (VSMC) can adversely modulate the
fractional engagement of collagen, leading to a dynamic
increase in stiffness.16-22 In fact, recent studies in a mouse
model, where viable smooth muscle preparations can be
readily obtained and activated with vasoactive agents to
measure active stiffness, have demonstrated that close to half
of the total stiffness of the aortic wall is attributable to the
active stiffness of the VSMC,16 with the remaining fraction
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due to the extracellular matrix. Furthermore, aging has
recently been shown to further increase the active stiffness
of the VSMCs23 in a mouse model.
In addition to the passive stiffness of the matrix, there are at
least 2 dynamic components that contribute to the material
stiffness of the VSMC: first, the attachment of cycling cross-
bridges in the contractile filaments, and, second, the regulated
transmission of force and stiffness through a nonmuscle actin
cytoskeleton connected to focal adhesion (FA) complexes. The
stiffness and plasticity of this nonmuscle actin cytoskeleton are
regulated by proteins that control branched and linear actin
polymerization such as N-WASP and VASP, respectively.20,24-26
The FA complexes include transmembrane integrins that
connect with the extracellular matrix of the aortic wall. Thus, it
has become clear in recent years that the contractile filaments
are not directly connected to the integrins.20
The nonmuscle actin cytoskeleton and FAs to which it is
attached have been shown to display plasticity in the
presence of agonists26 and biomechanical stimuli27,28 by
exhibiting stimulus-induced increases in actin polymerization
and endosomal-dependent remodeling of a subset of FA
proteins.29 Plasticity of the cortical cytoskeleton of VSMCs
may contribute to the function of the healthy, compliant
proximal aorta, acting as a tunable “shock absorber” that
adapts in order to limit transmission of excessive pulsatile
energy into the delicate downstream microvessels. This
plasticity of the cortical cytoskeleton of the aorta in young
mice has been shown to utilize a Src-dependent signaling
pathway that promotes tyrosine phosphorylation of FA
proteins.30 We have found that attenuated activity of this
pathway with aging is associated with stiffening, measured
ex vivo in a mouse model.16
In the present study we asked whether human single
nucleotide polymorphism analysis might support a link
between VSM cytoskeletal malfunction and aortic stiffness,
and we tested the hypothesis that specific cytoskeletal
protein-protein interfaces that no longer remodel in the aged
aorta could be competed with by decoy peptides to reduce
increases in aortic stiffness of proximal aortas taken from
aged mice. Because a simultaneous decrease of the stiffness
of all smooth muscle tissues would be disadvantageous, we
furthermore provide proof of concept for a microbubble-
mediated delivery of cytoskeletal decoy peptides to the aortic
smooth muscle that can be ultrasound targeted and therefore
shows promise as a novel potential therapeutic approach to
reverse cardiovascular aging.
Methods
The data, analytic methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure. This is due to
the cost of replicating the materials and limitations on the
sharing of the human data.
Experimental Animals and Aortic Sample
Preparation
All procedures were performed in accordance to protocols
approved by the Institutional Animal Care and Use Committee
of Boston University (Permit Number: A3316-01) and used in
compliance with federal, state, and local laws. C57BL6/J mice
were euthanized by isoflurane inhalation. Following euthana-
sia, aortas were quickly excised from young (3-4 months) or
aged (24-29 months) mice, placed directly in ice-cold mod-
ified Krebs solution ([mmol/L]: 154 NaCl, 5.4 KCl, 1.2 MgSO4,
10 MOPS, 5.5 glucose, and 1.6 CaCl2; pH=7.4), and cleaned
of excess perivascular fat. Axial rings that were 4 to 5 mm in
length were cut from the proximal end of the thoracic aorta
for biomechanical measurements and bath loading of
peptides.
Human Studies
The AortaGen Consortium included 20 634 participants with a
broad age distribution from 9 community-based cohort
studies that completed genome-wide genotyping and had
measured carotid-femoral pulse wave velocity (CFPWV). Each
study received institutional review board approval of its
consent procedures, examination and surveillance compo-
nents, data security measures, and DNA collection and use for
genetic research. All participants in each study gave written
informed consent for participation in the study and the
Clinical Perspective
What Is New?
• Aortic stiffness can be decreased in a mouse model of aging
by using decoy peptides that compete with cytoskeletal
protein-protein interfaces.
• The decoy peptides can be packaged onto microbubbles for
ultrasound-mediated targeting to the aorta.
• Genetic studies suggest that the same cytoskeletal path-
ways may be involved in aortic stiffness in humans.
What Are the Clinical Implications?
• Aortic stiffness increases with age and is an early and
independent biomarker for cognitive decline, myocardial
infarction, and renal disease.
• Although there is currently no approved therapy to reduce
aortic stiffness, our results indicate that cytoskeletal
peptides may represent novel therapeutic targets.
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conduct of genetic research. Details of study cohort, CFPWV
measurement protocols, and inclusion and exclusion criteria
are provided in the original publication.31
Expression and Purification of VASP EVH1-TAT
Recombinant Protein
VASP EVH1-TAT recombinant protein was expressed in a
pTYB1 vector (New England Biolabs, Ipswich, MA) and
purified on an affinity based chitin resin column as published
previously.26 Briefly, the EVH1-TAT construct was cloned in a
pTYB1 vector (New England Biolabs). This vector consists of a
chitin-binding domain (for affinity purification) and an intein
tag (for self-cleavage after purification). The construct was
expressed in BL21 (DE3) cells (Invitrogen, Carlsbad, CA),
which were grown in terrific broth medium at 37°C until an
optical density at 600 nm reached a value of 0.8. The
recombinant protein expression was induced by addition of
0.5 mmol/L Isopropyl b-D-thiogalactoside (Invitrogen), and
cultivation was continued at 20°C for 16 hours. Cells were
harvested by centrifugation, suspended in a column buffer
(20 mmol/L Na-HEPES, pH8.5, 500 mmol/L NaCl, 1 mmol/
L EDTA, 0.1% Triton X-100, and 20 lmol/L protease
inhibitor), and lysed by sonication. The soluble lysate was
then loaded on an affinity-based chitin resin column. VASP
EVH1-TAT recombinant protein was purified by standard
affinity chromatography procedure through a chitin column
(New England Biolabs, Ipswich, MA) and concentrated by
AmiconUltra-15 (Millipore, Burlington, MA). The protein
aliquots were flash frozen in liquid nitrogen and stored at
80°C until further use.
WASP Peptide Sequences
The human and mouse CA domain sequence used
is TSGIVGALMEVMQKRSKAIHSSDEDEDEDDEEDFEDDDEWED.
In parallel, as a control, we also synthesized a scrambled
peptide, identical except that the cytoskeletal sequence has
the amino acids arranged in a random order: for the CA
domain the scrambled sequence used is DEMLEQEKGDES-
GIDSGDKDMEEVADSWEVEDHSETDIADDE.
Synthesis of Cell-Permeant Fluorescently Tagged
Decoy Peptides
Peptide sequences were synthesized by solid-state peptide
synthesis using fluorenylmethoxycarbonyl chemistry to pro-
tect the amino groups. They were synthetically coupled to a
TAT protein transduction domain comprising residues
YGRKKRRQRRR. To add fluorescence labels to the peptides,
the side chain of the first lysine in the TAT sequence was
protected with the acid-labile 4-methytrityl, which was
selectively removed from the completed peptide sequence
using 5 to 8 consecutive 2-minute treatments with 2%
trifluoroacetic acid. The deprotected lysine side chain was
then coupled to fluorenylmethoxycarbonyl aminohexanoic
acid as a spacer, which, following removal of the fluorenyl-
methoxycarbonyl, was labeled with isothiocyanate derivatives
of the fluorophores.
Measurement of Aortic Geometry
Axial length, diameter, and wall thickness were quantitated to
determine cross-sectional area, used to calculate vessel
stress and stiffness. Axial length and slack diameter were
measured during dissection. For wall thickness measure-
ments, 1-mm length rings are cut just proximal and distal to
the tissue used for biomechanics. For visualization, the 1-mm
rings were incubated in nuclear stain (NucBlue, Life Tech-
nologies, Carlsbad, CA) for 30 minutes and then imaged
(920) with an Eclipse TE2000-E fluorescence microscope
(Nikon Instruments, Tokyo, Japan) via NIS-Elements software.
Fifteen to 20 measurements were recorded for each ring to
calculate the average wall thickness.
Biomechanics
Tissue stiffness in kilopascals was determined at baseline and
in the presence of the agonist phenylephrine (105 mol/L) at
the optimal length for force production with small-amplitude
(1% of tissue length), high-frequency (40 Hz) sinusoidal
stretches. Stiffness is defined as stress divided by the strain
in response to the sinusoidal oscillations, (DF/cross-sectional
area)/(DL/L0), where DF is the amplitude of the force
response to the cyclic stretches, DL is the amplitude of the
cyclic length changes, and L0 is the optimal length. Stress
was calculated as DF/cross-sectional area. This method does
not result in a phase lag of the force response and does not
cause detachment of actomyosin crossbridges.32
Aortic rings were mounted onto 2 wire triangles (0.01 inch
diameter). Once mounted, the vessels were incubated in
baths (50 mL) containing oxygenated (95% O2+5% CO2)
modified Krebs solution. The lower triangle was fixed, and
the upper triangle was attached to a lever arm connected to a
force transducer system (model 300C Dual-Mode Lever Arm
System by Aurora Scientific, Aurora, ON, Canada) and
monitored using chart software (AD Instruments, Dunedin,
New Zealand). Rings were stretched uniaxially in the circum-
ferential direction to the optimal length L0 (1.89slack length).
Steady-state force, F, was measured after equilibration for
30 minutes at that length. Each aortic ring was tested for
viability by contracting with a depolarizing solution (Modified
Krebs solution in which 51 mmol/L NaCl is replaced by
51 mmol/L KCl).
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Differential Centrifugation for Tissue
Fractionation
Aortic tissue was dissected and cleaned. Aortic strips were
quick frozen and placed in Precellys tube (Bertin Technologies,
Montigny-Le-Bretonneux, France) containing ice-cold 0.1 mL
buffer I containing 20 mmol/L Tris HCl, pH 7.5, 50 mmol/L
NaCl, 250 mmol/L sucrose, 10 mmol/L dithiothreitol,
3 mmol/L EGTA, 5 mmol/L MgCl2, 1 mmol/L ATP, and
protease inhibitor cocktail. The tissue was homogenized with
a Precellys 24 unit (Bertin Technologies, Montigny-Le-Breton-
neux, France) at 4°C. The homogenized tissue was centrifuged
at 100 000g for 1 hour at 4°C. The supernatant (cytosolic
fraction) was collected, and the pellet was dissolved in equal
volumes of buffer II containing 20 mmol/L Tris HCl, pH 7.5,
250 mmol/L sucrose, 10 mmol/L dithiothreitol, 3 mmol/L
EGTA, 5 mmol/L MgCl2, 0.5% Triton X-100, 1 mmol/L ATP,
and protease inhibitor cocktail. The resuspended pellet was
shaken for 1 hour at 4°C and centrifuged at 100 000g for
1 hour. This supernatant was collected as the membrane
fraction. The pellet was resuspended in buffer III (20 mmol/L
Tris.HCl, pH 7.5, 250 mmol/L sucrose, 10 mmol/L dithio-
threitol, 3 mmol/L EGTA, 5 mmol/L MgCl2, 0.5% Triton
X-100, 1.2% SDS, 1 mmol/L ATP and protease inhibitor
cocktail), shaken for 1 hour at 4°C and briefly centrifuged. The
final supernatant was collected as the cytoskeletal fraction.
Equal volumes of each fraction were loaded on SDS-PAGE for
further analysis of vinculin/metavinculin levels by Western
blotting with a monoclonal antivinculin antibody (catalog #
V9131, Sigma, St. Louis, MO) at 1:1000 dilution and IRDye
800CW goat antimouse secondary antibody (catalog # 925-
32210, LI-COR Biosciences, Lincoln, NE) at 1:10 000 dilution.
Vinculin/metavinculin levels were determined by scanning
band densitometry on the raw images obtained using an
Odyssey IR imaging system (LI-COR). Data are presented as a
percentage of total vinculin/metavinculin.
Aortic Cell Culture
A7r5 aortic smooth muscle cells (ATCC, Manassas, VA) were
cultured on coverslips in DMEM high glucose with 10% fetal
calf serum, 1% glutamine, 50 units/mL penicillin, and 50 lg/
mL streptomycin. Before experimentation, cells were serum
starved for 24 hours to drive them to a differentiated
state.33,34 To confirm permeation of the peptides into cells,
cultured A7r5 cells were either unloaded or loaded for
30 minutes at 37°C with 250 lmol/L N-WASP CA domain or
100 lmol/L TLN-VCL fluorescently labeled constructs. For
focal adhesion assays, 50 lmol/L TLN-VCL was used.
Filamentous actin was stained with Alexa Fluor 488
phalloidin (1:3000, Invitrogen, Carlsbad, CA). Cells were
examined with an Eclipse TE2000-E fluorescence microscope
(Nikon Instruments) using a Nikon Plan Apochromat oil-
immersion objective and a charge-coupled device camera
(CoolSNAP HQ2, Photometrics, Tucson, AZ). NIS-Element
Advanced Research software (Nikon Instruments) was used to
capture images for removal of out-of-focus fluorescence blur
in tissues by deconvolution of Z-sections (Richardson-Lucy
algorithm, constrained iterative–maximum likelihood estima-
tion algorithm). Images from control and construct-loaded
samples were obtained at identical microscope and software
settings (look-up tables, offsets, and gains).
Focal Adhesion Integrity Assay
To analyze the focal adhesion size and number, A7r5 cells
were grown on glass coverslips. Cells were serum-starved for
24 hours followed by treatment with 50 lmol/L scrambled
TLN-VCL or TLN-VCL construct for 30 minutes at 37°C. The
cells were rinsed in PBS and fixed in 4% paraformaldehyde.
Cells were then permeabilized and blocked concurrently with
0.1% Triton X-100 in 1% BSA and 10% normal goat serum for
1 hour at room temperature. Labeling was accomplished with
antivinculin antibody (1:200, V9131, Sigma, St. Louis, MO).
For the secondary antibody, we used Alexa Fluor 488
conjugated goat antimouse IgG (H+L) (1:400, A11029 Invit-
rogen). F-actin was stained with Alexa Fluor 568 Phalloidin
(1:400, A12380, Invitrogen). Coverslips were mounted on
glass slides with fluorsave mounting medium with DAPI
(ab104139, Abcam, Cambridge, UK).
The cells were examined with an Eclipse TE2000-E fluores-
cence microscope (Nikon, Tokyo, Japan) equipped with a Nikon
Plan Apochromat 609 (NA 1.4) oil-immersion objective and a
charge-coupled device camera (CoolSNAP HQ2, Photometrics,
Tucson, AZ). Images were acquired by NIS-Element Advance
Research software. Only peripheral focal adhesions (5-10 lm
from cell edge) were measured using NIS-Element AR Software.
Focal adhesions were measured for 4 to 7 cells per condition
(control, scrambled, TLN-VCL) in 5 independent experiments
each. Focal adhesion numbers were counted manually.
Microbubble Peptide Complex Production
The microbubbles were made from a lipid solution and
octafluoropropane gas via mechanical agitation. The lipids
distearoylphosphocholine, distearoylphosphoethanolamine-
PEG2000 (Avanti Polar Lipids, Inc, Alabaster, AL), and
distearoylphosphoethanolamine-PEG3400 linked with pep-
tide-FITC were mixed at a molar ratio of 8:1:1 and a final lipid
concentration of 5 lmol/mL in chloroform. The lipid solution
was dried under vacuum overnight, and the resultant thin lipid
filmwas rehydrated in a solution of 10% glycerol, 10% propylene
glycol, and 80% deionized water. The lipid suspension was
sonicated for 1 minute and degassed at room temperature.
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After saturation of the lipid solution with octafluoropropane gas
(Fluoromed, Round Rock, TX), the solution was shaken
vigorously, producing polydispersed lipid-coatedmicrobubbles.
Bath Loading of Peptides Into Ex Vivo Aortic
Tissue and Tissue Imaging
From lyophilized powder, loading solutions were prepared by
dilution to final working concentrations (100 lmol/L for TLN-
VBS and EVH1, 250 lmol/L for N-WASP) in modified Krebs
solution and incubated with aortic rings for 30 minutes at
37°C in 1-mL loading trays containing a disk of polydimethyl-
siloxane gel at the bottom of the well. Each aortic ring was
threaded with a triangular wire clasp parallel to a piece of
straight wire and then transferred to the loading tray. The
tissue was stretched with small surgical pins to the physio-
logic strain (180% of slack length) by pulling the triangular
clasp and wire apart to the precise length as measured with a
reticule in a dissecting microscope. The tray was positioned
atop a heating bath at 37°C. Successful peptide loading was
confirmed at the end of each experiment by cutting a 1-mm-
length ring, staining nuclei for orientation with NucBlue (Life
Technologies, Carlsbad, CA), and examining with an Eclipse
TE2000-E fluorescence microscope (Nikon Instruments,
Tokyo, Japan) as described in the above section using a
Nikon Plan Apochromat oil-immersion objective and a charge-
coupled device camera (CoolSNAP HQ2, Photometrics, Tuc-
son, AZ). NIS-Element Advanced Research software (Nikon
Instruments) was used to capture images and for removal of
out-of-focus fluorescence blur in tissues by deconvolution of
Z-sections. Tissue images shown are deconvolved images. In
all cases images from peptide-loaded or control samples were
obtained at identical microscope and software settings (look-
up tables, offsets, and gains).
Actin Polymerization Assay
Aortic tissue strips (8 mg wet weight) were placed in 0.5-mL
soft tissue homogenizing tubes (Precellys, Bertin Technolo-
gies, Montigny-Le-Bretonneux, France) containing prewarmed
lysis and F-actin stabilization buffer (50 mmol/L PIPES pH 6.9,
50 mmol/L NaCl, 5 mmol/L MgCl2, 5 mmol/L EGTA, 5% [v/v]
Glycerol, 0.1% Nonidet P40, 0.1% Triton X-100, 0.1% Tween 20,
0.1% 2-mercapto-ethanol, 0.001% Antifoam C) with 1 mmol/L
ATP and protease inhibitor cocktail (Cytoskeleton, Inc, Denver,
CO). The tissue was quickly homogenized in a tissue homog-
enizer (Precellys 24, Bertin Technologies, Montigny-Le-Breton-
neux, France), and 100 lL of lysates was incubated at 37°C
for 20 minutes and then spun at 150 000g for 60 minutes at
37°C in an Optima TLX ultracentrifuge (Beckman Coulter, Brea,
CA). The supernatant fraction (G-actin) was removed gently to
avoid disturbing the F-actin pellet. Then, 100 lL of ice-cold
F-actin depolymerization buffer (8 mol/L urea) was added to
each pellet. The pellet was dissolved by pipetting up and down
several times every 15 minutes for 1 hour. To remove cell
debris, this solution was spun at 2300g for 5 minutes (4°C),
and the supernatant was collected to give the final F-actin
fraction. The samples were stored at 80°C until further
separation by SDS-PAGE and immunoblotting with an antiactin
primary antibody (Cytoskeleton) and a secondary IRDye 680–
labeled goat antirabbit (LI-COR, Lincoln, NE) and visualized on
an Odyssey infrared imaging system (LI-COR [Lincoln, NE]) for
densitometric analysis with Odyssey 2.1 software. All analyses
were performed on raw data.
Conjugation to Lipid for Microbubbles
Before the microbubble formation, the peptides were
conjugated directly to lipid using a thiol-maleimide reaction.
In general, distearoylphosphoethanolamine-PEG3400-malei-
mide (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[maleimide(polyethylene glycol)-2000], ammonium salt)
(Nanocs, PG2-DSML-3k) was dispersed via sonication at a
concentration of 0.04 mmol/L in PBS, pH 7.4 (or ultrapure
water, pH 7.0) to create micelles. Micelle formation was
verified via dynamic light scattering. Separately, the peptide
was dissolved in modified Krebs solution (pH 7.4) containing
5 mmol/L EDTA. The lipid and peptide solutions were mixed
in a 1:1.25 molar ratio and stirred, protected from light, for
24 hours at room temperature to ensure development of the
thiol-ester bond. Free peptide was separated from the protein-
lipid conjugate using centrifugal filtration. In brief, the peptide
solution along with 3 mL ultrapure water was added to the
filter (MWCO 10 kDa, Amicon, EMD Millipore, Billerica, MA),
and spun for 10 minutes at 4000g. This process was repeated
3 times to wash the conjugate and to exchange the buffer.
The peptide-lipid was then lyophilized and resuspended in
chloroform (1 mg/mL) for use in the microbubbles. Conjuga-
tion was confirmed via fluorescent microscopy of subse-
quently produced microbubbles.
Microbubble-Peptide Complex Introduction Into
Aortic Segments
A suspension of microbubbles loaded with peptide at a
concentration of 0.2 lmol/mL was injected into the lumen of
an excised murine aorta. The ends of the aorta were sealed,
and the vessel was placed at the focus of a 1-MHz focused
transducer (Panametrics A392S, Waltham, MA) in a water
bath. The focused transducer transmitted 200-cycle ultra-
sound pulses with a frequency of 1-MHz and acoustic
pressure of 978 kPa at a pulse repetition frequency of 1 Hz
for 30 seconds to fragment microbubbles, release the
peptide, and reversibly disrupt the endothelium.
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Statistics
We evaluated the contribution of common genetic variation at
the N-WASP locus (gene symbol WASL) to aortic stiffness in
humans by interrogating results of the CFPWV genome-wide
association study performed by the AortaGen Consortium.31
The standardized phenotype in the AortaGen analysis was 1/
CFPWV, which was adjusted for age,2 height, and weight and
then transformed to standardized Z-values (mean=0 and
SD=1). However, because the phenotype was inverse CFPWV,
a positive B corresponds to lower CFPWV (less stiff aorta), and
a negative B corresponds to higher CFPWV (stiffer aorta). We
selected single nucleotide polymorphisms that fell within
20 kb of the WASL gene and were nonredundant at an
R2>0.30. These selection criteria identified 9 single nucleotide
polymorphisms in the WASL locus. Therefore, we prospec-
tively set a gene-wise Bonferroni-adjusted threshold for
significance at P<0.05/9=0.0056.
Values are presented as meanSEM. Analysis was carried
out using the GraphPad Prism (7.0) software (La Jolla, CA). For
actin polymerization and ex vivo biomechanics comparisons,
groups were compared using a Student t test (2-tailed) for
parametric data. Significance was assumed at P<0.05 except
as noted above and indicated in the figures with an asterisk.
Results
Human Single Nucleotide Polymorphism Analysis
Supports a Link Between Vascular Smooth
Muscle Cytoskeletal Function and Aortic
Stiffness
Results are detailed in Table. We found evidence for
association at rs600420 (P=0.0051). Local linkage
disequilibrium for rs600420 is plotted in Figure 1, prepared
by using SNAP,35 which demonstrates evidence for a region of
linkage disequilibrium that spans the WASL gene.
Previous studies on animal models have shown an
involvement of the N-WASP protein from the WASL gene in
the regulation of actin polymerization and contractility in
smooth muscle of mammalian airways,36 but effects on aortic
stiffness have not been determined. Thus, N-WASP was an
attractive candidate molecule to pursue with a decoy peptide
strategy to determine effects on stiffness.
Strategy of Decoy Peptide Design
The CA domain of N-WASP is a subset of the C-terminal VCA
domain by which N-WASP activates the Arp 2/3 complex,
inducing actin polymerization at branches from the side of
parent actin filaments.36,37 The CA domain binds to G-actin,
and because it lacks the V domain, acts as a dominant negative
inhibitor of N-WASP-mediated actin polymerization in airway
smooth muscle,36 but its effects in vascular smooth muscle are
unknown. In order to test the novel idea that the CA peptide
and other decoy cytoskeletal peptides might function as a
useful approach to inhibit aortic stiffness and vascular
contractility, we synthesized a series of constructs using the
generic design illustrated in Figure 2A to incorporate the TAT
cell permeation tag38,39 and a fluorescent tag together with the
peptide. A scrambled CA sequence was used as a control.
Decoy Peptides Can Be Introduced Into Vascular
Smooth Muscle Cells of the Blood Vessel Wall
When Coupled to a Cell Permeation Sequence
The left-hand panels of Figure 2B show images of A7r5 aortic
cells that were subjected to serum starvation and labeled with
Table. Association Results for Carotid-Femoral Pulse Wave Velocity From the AortaGen Consortium
SNP ID Allele1 Allele2 Effect Allele
Effect Allele
Frequency Location on Chr 7 B SE P Value
rs12706544 A C C 0.23 123092680 0.032 0.013 0.014
rs1019219 T C C 0.08 123106873 0.014 0.020 0.497
rs1073682 G C C 0.99 123110320 0.019 0.061 0.753
rs6971373 A G G 0.01 123121498 0.016 0.063 0.795
rs6975039 T C C 0.93 123134504 0.015 0.022 0.486
rs12706551 T G G 0.96 123166013 0.059 0.031 0.060
rs2069269 G C C 0.92 123193642 0.022 0.020 0.280
rs623201 T C C 0.23 123194511 0.014 0.013 0.299
rs600420 A G G 0.60 123195286 0.031 0.011 0.005
Carotid-femoral pulse wave velocity was inverted and standardized before analysis. B indicates difference in standardized inverse carotid-femoral pulse wave velocity per dose of the coded
allele; Chr, chromosome; SNP, single nucleotide polymorphism.
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phalloidin (green) for actin. The cells were serum starved to
promote a differentiated phenotype. The top image shows
control cells to which no construct was added. The lower
image shows similar cells but to which the rhodamine-labeled
N-WASP CA decoy peptide was added, demonstrating incor-
poration into the cells.
The right-hand panels show aortic tissue preparations
stained with DAPI (blue) to locate nuclei for orientation. No
construct was added to the top tissue. The bottom image is of
another aortic preparation, taken with identical microscope
acquisition and software settings, stained with DAPI but also
loaded with a rhodamine (red)-labeled peptide for 30 minutes,
which is clearly detectable in the smooth muscle cells of the
wall. Thus, we are able to load decoy peptides successfully
into aortic smooth muscle tissue by virtue of the cell
permeation tag alone.
N-WASP CA Domain Introduced Ex Vivo Into
Young and Old Mouse Aortas Decreases Aortic
Stiffness
As we have previously reported,23 ex vivo mouse aorta
preparations display a significantly higher level of a
agonist–activated stiffness when taken from aged animals
compared with young animals (Figure 2C top graph, black
bars, right versus left). Furthermore, when aortas from both
young and aged mice were bath loaded with the N-WASP
CA domain decoy peptide, active stiffening of the aortas in
the presence of phenylephrine was reduced (Figure 2C top
graph, black bar versus white bar). The decoy peptide also
inhibited the contractile stress response to phenylephrine in
aortic preparations from young mice (lower panel). The
decreased stress response is expected because the cortical
cytoskeleton, which transmits forces generated by the
contractile filaments to the integrins and the vessel wall,
has been targeted by this construct. But, interestingly,
stress was not significantly changed in aged mice,
suggesting a difference in mechanisms of force generation
or transmission with age. No change in unstimulated, ie,
baseline stiffness or stress was seen with the peptide,
consistent with these parameters being set constant by
passive extracellular matrix responses at these levels of
tissue stretch.
A Decoy Construct From the EVH1 Domain of
Ena-VASP Family Proteins, Targeted to a Different
Mechanism of Actin Polymerization, Is Also
Effective in Decreasing Ex Vivo Aortic Stiffness of
Aortas From Young and Old Mice
We were next interested in whether a decoy peptide strategy
is more broadly applicable. Actin polymerization can occur in
2 major ways in cytoskeletal structures: (1) by the activation
of the Arp 2/3-N-WASP complex, which adds branched
Figure 1. Regional linkage disequilibrium plot for rs600420. The span of single nucleotide polymorphisms
with an R2>0.80 is indicated by the vertical dashed lines. The WASL gene lies within this region of linkage
disequilibrium. Figure was prepared by using the Scalable Nucleotide Alignment Program (SNAP).35
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actin, or (2) by linear extension of the barbed end of actin
filaments by the activity of the ena-VASP family of
cytoskeletal proteins.40 The latter has been shown by our
group to occur in vascular smooth muscle in a regulated
manner.26 Hence, we determined whether regulation of
linear actin polymerization could be targeted to decrease
ex vivo aortic stiffness. The N-terminal EVH1 domain of ena-
VASP family members localizes VASP to zyxin in vascular
Figure 2. Decoy constructs targeted to actin polymerization molecules decrease aortic stiffness. A, Top, Design of prototype for cell-permeant
decoy peptides. Blue type, protein-specific domain sequence, acetylated on the N-terminus to maintain stability. N-WASP CA dominant negative
peptide sequence shown. Red type, sequence derived from the TAT known to be a cell permeation sequence38,39 added to C-terminus. Green
type, a fluorescent dye (FITC or rhodamine) added to an e-aminohexanoic acid (AXH) bridge as a side chain off a lysine of the TAT sequence in
order to confirm intracellular loading. The AHX bridge allows the fluorophore to be added without adverse effects on peptide stability. Bottom,
Diagram illustrating the method of inhibition by the decoy peptide. The CA domain inhibits the binding of N-WASP to the Arp2/3 complex and
prevents its activation. B, Decoy constructs permeate into aortic cells (left) and tissue (right). Left panels, No added construct (top) or
rhodamine-labeled (red) N-WASP CA peptide-loaded cells (bottom). Costained with phalloidin (green) for actin. Incorporated peptide is especially
noticeable in the perinuclear region, the thickest part of the cell. Right panels, No added construct (top) or rhodamine-labeled N-WASP CA
peptide-loaded into ex vivo aortic tissue (bottom). Tissue costained with DAPI to locate nuclei. Images are obtained at identical microscope and
software settings (look-up tables, offsets, and gains). Scale bars: 20 lm. C, Top panel, Aortic tissues from aged mice show significantly
increased active, PE-induced stiffness compared with those from young mice (black bars). The introduction of the N-WASP CA domain peptide
(white vs black bars) significantly decreases active stiffness (top panel) in both young (3-month-old, n=6) and old (24-29 months, n=6) mice. The
peptide decreases PE-induced stress significantly only in young mice (bottom panel). Asterisks indicate significant differences (P<0.05) from
scrambled peptides. D, Top panel, Aortic tissues from aged mice show significantly increased active, PE-induced stiffness compared with those
from young mice (black bars). Decoy construct targeted to EVH1 decreases PE-mediated aortic stiffness (top panel) and stress (bottom panel)
(tan vs black bars) ex vivo in young (n=12) and aged (n=7) mice. Asterisks indicate significant differences P<0.05 from control peptides. E,
Inhibition of PE-induced actin polymerization (n=7, young adult, 3- to 4-month-old mice) by the N-WASP CA domain peptide (n=8) and EVH1
construct (n=8), compared with baseline values (n=7), demonstrate on-target effects. PE indicates phenylephrine.
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FAs, facilitating linear actin polymerization at those
sites.41,42 Because of the length of the EVH1 domain, we
synthesized the analogous decoy construct by making EVH1
domain, attached to the TAT cell permeation tag, as a
recombinant protein. This protein was bath loaded into
aortic rings ex vivo and, as shown in Figure 2D, was
effective in decreasing both stiffness (top panel) and stress
(bottom panel) compared with control loading in young and
aged mice. The control used was either a mutant (Phe78Ser)
EVH1 domain, which has no effect on contractility,26 or
sham loading with no peptide. No significant difference
(P<0.05) was seen between the use of these 2 controls on
either stiffness or stress so their values are merged in
Figure 2D.
We further confirmed that the effects of these 2 types of
decoy constructs, designed to interfere with actin polymer-
ization mechanisms, altered biomechanics by on-target,
direct effects on actin polymerization (Figure 2E). The
phenylephrine-induced increase in actin polymerization as
shown by the actin filamentous/globular actin ratio was
significantly decreased by both the WASP CA domain and
EVH1 constructs, essentially to unstimulated levels.
A Decoy Peptide Based on a Protein-Protein
Interface Between FA Proteins is Also Effective in
Decreasing Ex Vivo Aortic Stiffness in Aortas
From Young and Old Mice
Given that FA remodeling in smooth muscle has been shown
to occur in response to vasoactive stimuli,29,43 and that Src-
dependent pathways of FA remodeling are lost with aging,16
we asked whether protein-protein interfaces in the FA
complex could be targeted with a similar cell-permeant decoy
peptide approach. Based on the widely known importance of
interactions of vinculin with talin in the FA,44,45 we designed a
peptide (TLN-VCL) mimicking a vinculin binding site on talin.
There are several talin-vinculin binding sites, and although
several of these sequences had no effect on smooth muscle
cell function, the sequence GRPLLQAAKGLAGAVSELLRSAQPA
was effective. A scrambled version of this peptide,
LLRRSQAALGAAAEVLPQALSGPGK, was used as a control.
The sequence was substituted for the N-WASP sequence in
the generic construct described in Figure 2A. We demon-
strate, in Figure 3A, the ability of the construct to incorporate
into smooth muscle cells in both serum-starved aortic cells
(Figure 3A, left column, bottom panel compared with
unloaded cells, top panel) and tissue (Figure 3A, right column,
bottom panel compared to unloaded tissue, top panel). The
construct is also effective in decreasing tissue stiffness
(Figure 3B, top) and stress (Figure 3B, bottom) after bath
loading at 100 lmol/L in proximal aortas from both young
and aged animals.
We next sought to confirm that the TLN-VCL peptide
disrupts cytoskeletal/contractile complexes by an on-target
effect of interfering with vinculin binding to talin. To do this,
we used a focal adhesion redistribution assay as described in
Methods. Aortic tissue was fractionated into cytosolic,
membrane, and cytoskeletonal fractions by differential ultra-
centrifugation, allowing the determination of the subcellular
location of vinculin in the 3 fractions. In addition to vinculin
itself, smooth muscle also expresses the slightly larger
metavinculin, which is a muscle-specific splice variant of
vinculin.46 We analyzed the amounts of both vinculin and
metavinculin in each fraction by immunoblot. In TLN-VCL
peptide–treated tissue, the amount of vinculin/metavinculin
was significantly decreased in the membrane fraction
compared with control tissue not exposed to peptide. In
parallel, the vinculin/metavinculin in the cytoskeletal fraction
of peptide-treated tissue was increased as compared with
control tissue (Figure 3C). Altogether, these data are consis-
tent with the concept that the TLN-VCL peptide decreases
stress and stiffness by disrupting cytoskeletal protein-protein
interfaces (Figure 3D).
To further confirm that the TLN-VCL peptides altered focal
adhesion integrity, we used a model system, the serum-
starved A7r5 cells. Although this cultured cell line is
noncontractile, these A7r5 cells express vascular smooth
muscle differentiation markers when serum starved. When
these cells were treated with the same concentration of TLN-
VCL peptide as shown above to decrease vessel stiffness,
we noticed that focal adhesions were very difficult to
visualize. Thus, we decreased the concentration of the TLN-
VCL peptide to half of that used for the biomechanics
experiments, ie, to 50 lmol/L. At this lower concentration,
we quantitated the size and number of peripheral focal
adhesions in cells treated with either control (scrambled
peptide) or TLN-VCL peptides.
Typical cell images for cells exposed to no peptide
(control), scrambled TLN-VCL peptide, and TLN-VCL peptide
are shown in Figure 4A. In general, both control cells and cells
treated with the scrambled peptide show numerous peripheral
focal adhesions, but the TLN-VCL–treated cells show sparse,
small focal adhesions. We quantitated these findings by
measuring the area of individual FAs (Figure 4B) and the
number of peripheral FAs per cell (Figure 4C). As can be seen
in Figure 4B, no significant difference occurred between the
control and scrambled peptide–treated cells in FA size, but
the cells treated with TLN-VCL peptide displayed a significant
decrease in FA size. Similarly, as shown in Figure 4C, no
difference was detectable between the control and scrambled
peptide–treated cells with respect to the number of peripheral
FAs. However, the FA number was significantly decreased in
the cells treated with the TLN-VCL peptide. Thus, the TLN-VCL
peptide directly alters FA properties.
DOI: 10.1161/JAHA.118.008926 Journal of the American Heart Association 9
Cytoskeleton and Cardiovascular Aging Nicholson et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on March 22, 2019
Figure 3. Decoy construct targeted to focal adhesion protein-protein interfaces decrease aortic stiffness through an on-target cytoskeletal
mechanism. A, Immunofluorescent images demonstrate that the decoy talin-vinculin (TLN-VCL) construct permeates into aortic cells and tissue
ex vivo. Left panels, Rhodamine-labeled (red) TLN-VCL construct loaded cells (bottom) or not loaded (top). All cells costained with phalloidin
(green) for actin. Right panels, Rhodamine-labeled (red) TLN-VCL construct loaded into ex vivo aortic tissue (bottom) or not loaded (top). Both
tissues costained with DAPI (blue) for nuclei. Scale bars: 20 lm. All images were obtained with identical microscope settings. B, Targeting of the
talin-vinculin binding interface in FAs decreases PE-induced stiffness (top) and stress (bottom) in young (n=12, left panels) and aged (n=7, right
panels) mice. Asterisks indicate significant differences (P<0.05) between TLN-VCL peptide and scrambled peptide or between ages.
C, Fractionation of aortic tissue by differential ultracentrifugation demonstrates that TLN-VCL disrupts cytoskeletal integrity. Top, Representative
Western blots depicting metavinculin (top band) and vinculin (bottom band) from cytosolic (Cyt), membrane (Mem) and cytoskeletal (Csk)
fractions from control (no peptide), sham loaded, tissues (left, n=9) and TLN-VCL–treated (right, n=9) aortic tissue. Bottom, vinculin/
metavinculin in each fraction expressed as a percentage of total vinculin/metavinculin. D, Model of mechanism by which TLN-VCL decoy
construct reduces ex vivo aortic stiffness. Left, Talin binds integrins at plasmalemma. Vinculin binds talin to facilitate transmission of force and
stiffness from the actin cytoskeleton through the integrins to the extracellular matrix. Right, TLN-VCL decoy peptide reduces vinculin binding to
talin at the membrane, attenuating force and stiffness transmission to the extracellular matrix.
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Coupling of Peptides to Microbubbles Allows
Ultrasound-Mediated Targeting Deep Into the
Aortic Wall
The question arises as to how these peptides could be
introduced into the aortic media in a living organism. One
possibility is to use microbubbles47 to sequester the peptides
after injection into the bloodstream and then to use ultrasound
to create targeted release into only the proximal aorta. As is
shown in Figure 5B, a FITC-labeled TLN-VCL peptide was
conjugated to lipid-coated microbubbles through a stable
thioether linker. The linkage sequesters the peptide, but the
peptide can be released inside the aorta by fragmenting the
microbubbles with ultrasound pulses transmitted by a 1.1-MHz
focused transducer (Figure 5A). Stresses generated during
bubble oscillation and destruction can permeabilize the
endothelium reversibly48 and allow the peptide to cross the
intima and reach smooth muscle cells in the media of the aorta.
In Figure 5C, lower panel, the tissue has been ultrasound-
loaded, and the green peptide is seen appearing in cells at least
half way across the thickness of the vessel wall. A summary of
biomechanics measurements made on these tissues is shown
in Figure 5D, where loading of a scrambled TLN-VCL sequence
peptide attached to microbubbles has no effect (black bar).
Additionally, the active peptide, when attached tomicrobubbles
in the absence of ultrasound has no effect (gray bar). The latter
result confirms that the microbubbles do effectively sequester
the peptide. In contrast, ultrasound-released microbubble-
attached active peptides significantly decrease vessel stiffness
(green bar). This, therefore, illustrates a potential approach by
which these decoy peptides could be targeted to the aorta to
reverse increased aortic stiffness.
Thus, we can successfully target vascular smooth muscle
cytoskeletal function in 3 different ways: by interfering with
the talin-vinculin binding interface, the VASP EVH1 domain, or
the N-WASP CA domain.
Figure 4. Talin-vinculin (TLN-VCL) decoy construct decreases focal adhesion size and number in A7r5
cells. A, Immunofluorescence microscopy of representative serum-starved A7r5 cells treated with no
peptide (control), rhodamine-labeled scrambled peptide, or rhodamine-labeled TLN-VCL peptide. Cultured
A7r5 cells were treated for 30 minutes with either scrambled or TLN-VCL peptides followed by
immunolabeling with vinculin to image focal adhesions (green) and phalloidin to image actin filaments (red).
Nuclei were stained with DAPI (blue). Scale bars: 10 lm. B, Focal adhesion area is significantly decreased in
cells treated with TLN-VCL peptide as compared with cells treated with scrambled or no peptide.
C, Treatment with the TLN-VCL peptide significantly reduced focal adhesion numbers in A7r5 cells
compared with scrambled peptide–treated cells or no peptide. No significant difference was seen in focal
adhesion size and number in control cells compared to scrambled peptide–treated cells (n=65 cells).
****P<0.0001, 1-way ANOVA, Tukey multiple comparisons test. FA indicates focal adhesion.
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Discussion
We have previously reported that increased aortic stiffness
with aging, as measured in vivo by pulse wave velocity, occurs
in C57BL/6J mice.23 We have also observed an age-related
increase in ex vivo activated smooth muscle stiffness of the
mouse.16 Indeed, there is now a significant amount of
evidence from multiple laboratories to suggest that the
smooth muscle cell contributes significantly to the
development of age-related increases in active aortic
stiffness.16-22,49,50 Our findings point to the FA complex and
the attached, nonmuscle actin cytoskeleton as key sources
for the increase in smooth muscle cell stiffness.
The data presented here are consistent with a model in
which an age-related impairment of FA signaling leads to
impaired plasticity of VSMCs. We have previously demon-
strated that Src tyrosine kinase is essential in the regulation
of VSMC stiffness through its effects on a program of FA and
actin cytoskeletal remodeling pathways. The tyrosine phos-
phorylation of the FA proteins CAS pY-165, FAK pY-925, and
paxillin pY-118 causes FA remodeling,20,50,51 which we
previously found to occur through an endocytic recycling
pathway, allowing cyclic remodeling of the FAs. The mecha-
nisms that trigger the growth or degradation of individual FAs
in the intact aorta are controversial, but the previously
described concept of “slip” and “catch” bond formation at
high versus low forces, respectively,52 may apply. Perhaps
during the high forces of systole, some focal adhesion
proteins break loose from the FA and enter into endosomal
recycling pathways, allowing compliance and expansion of the
aorta, but during lower, diastolic, forces, the FA surface
rebuilds, promoting the return to the diastolic aortic diameter.
This process may be typical of the young compliant aorta, but
it appears to be lost in the aged, stiffened aorta.
Figure 5. Coupling of peptides to microbubbles allows ultrasound-mediated targeting into the aortic wall.
A, Ultrasound apparatus used to release decoy peptide and load it into aortic tissues from young animals by
bursting the microbubbles. B, Microbubbles coated with phospholipids conjugated to green FITC-labeled
peptides. C, Top, An unloaded ring with blue DAPI labeling of nuclei. Bottom, Green peptide loaded into cells
by ultrasound-mediated destruction of the peptide-coated microbubbles. Both panels were obtained at
identical microscope settings. D, Ultrasound-mediated release of TLN-VCL peptide decreases PE-induced
stiffness (green, n=6). No effect on stiffness was observed after ultrasound-mediated release of scrambled
peptide (black, n=5) or by passive diffusion of TLN-VCL peptide conjugated to microbubbles (grey, n=3).
*Difference between the bracketed bars is significant at a level of P<0.05.
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Therefore, the FA remodeling pathway is a rational target
for efforts designed to reduce aortic stiffness. Indeed, we
show here that the targeting of the talin-vinculin interface with
a synthetic decoy peptide directly decreases FA size and
number in serum-starved A7r5 vascular smooth muscle cells
and attenuates ex vivo stiffness, providing further evidence
that the focal adhesion complex is a key modulator of
vascular stiffness. Similarly, in the presence of peptides
designed to interfere with actin polymerization, the actin
peptides decrease actin polymerization as measured by the
filamentous/globular actin ratio and decrease ex vivo stiff-
ness. In future studies it will be of interest to see if this
approach is more broadly effective in additional situations
involving integrin signaling, which could be relevant not only
to vascular muscle function but also to endothelial function,
where changes in endothelial stiffness or adhesion of
leukocytes induced by inflammatory cytokines have been
demonstrated.53
Additionally, we demonstrated an association between
increased vascular stiffness and common genetic variation of
the gene encoding N-WASP by interrogating results from the
AortaGen Consortium genome-wide association study of
CFPWV. The AortaGen Consortium focused on CFPWV
because it is the gold standard for clinical assessment of
aortic stiffness.54 CFPWV has been shown to predict risk for
cardiovascular disease and to reclassify risk after accounting
for standard cardiovascular disease risk factors.2,55
Because N-WASP has previously been demonstrated to
modulate smooth muscle contraction through actin polymer-
ization/depolymerization pathways, we considered it as a
candidate to influence vascular stiffness. Indeed, a decoy
peptide targeted to the N-WASP CA domain is effective in
decreasing ex vivo aortic stiffness by directly inhibiting actin
polymerization. In addition, by inhibiting VASP function using
an EVH1 recombinant protein construct, we demonstrated
that ex vivo stiffness could also be attenuated by influencing
this separate actin polymerization pathway in vascular
smooth muscle. Therefore, in the current study, we have
shown, for the first time, that aortic stiffness can be
modulated by targeting these 2 separate types of interfaces,
FA protein-protein and actin-actin protein interfaces. We
propose that the connections between the FAs and the
nonmuscle actin cytoskeleton allow force and stiffness
generated by the contractile filaments to be transmitted to
the extracellular matrix. We found both strategies to be
effective in decreasing ex vivo stiffness following VSMC
activation. In vivo, this activation of the VSMC is likely
caused by circulating catecholamines, inflammatory angio-
tensin receptor stimulation, or other circulating vasoactive
agents.
We have shown here that the permeation tag and design
of these peptides allow passive diffusion of the peptides
into the vascular smooth muscle cells. With aging,
additional barriers may arise from increased thickness and
stiffness of the adventitia, but because luminal delivery is
planned, we do not anticipate this to cause significant
difficulties.
Importantly, we also report that by coupling the peptides
with microbubbles and triggering release via ultrasound, we
can generate focused ultrasound-targeted microbubble deliv-
ery of the peptides into the media of the aortic wall, where the
cell permeation moiety of the peptides can carry them into
the intracellular space. It is possible that the endothelial cells
may produce some age-related changes in their barrier
function, but the cavitation forces caused by microbubble
rupture should be able to overcome any unexpected age-
related increases in the endothelial barrier.
There are limitations to our study that should be
considered. Alteration of aortic stiffness with decoy pep-
tides might cause other sorts of dysfunction. If the
ultrasound-mediated peptide release is targeted exclusively
to the proximal aorta, adverse effects on the resistance
vessels would be avoided. However, the decoy peptides
decrease local vascular tone. Increased smooth muscle tone
is known to increase damping of high-frequency energy
content, which raises concerns that too much of a decrease
in stress and stiffness could promote thoracic aortic
aneurysm. An inverse relationship between higher vessel
wall stiffness and lower risk for aneurysm has been
reported56 in patients with diabetes mellitus, where there
is a decreased incidence of thoracic aortic aneurysms and
dissection, which is thought to be due to protective cross-
linking of structural proteins. Additional study may be
warranted to test the hypothesis that excessive reduction in
aortic stiffness could have the negative side effect of
increasing risk for aneurysm development. In vivo aging
studies, first in animal models and eventually in human
patients, will be needed to test all of these possibilities.
Finally, cohorts included in the AortaGen Consortium meta-
analysis comprised exclusively white participants of Euro-
pean descent. Thus, our findings may not be generalizable
to other racial or ethnic groups.
Conclusions
We have shown here that, first, perturbation of the
cytoskeleton of the vascular smooth muscle cell can
modulate aortic stiffness; second, it is possible to modulate
this process with microbubble-loaded decoy peptide con-
structs targeted to vascular smooth muscle cytoskeletal
protein-protein interfaces; and, third, genetic studies suggest
that similar pathways may be involved in aortic stiffness in
humans.
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